News of the WeekGene Therapy

What to Do When Clear Success Comes With an Unclear Risk?

See allHide authors and affiliations

Science  18 Oct 2002:
Vol. 298, Issue 5593, pp. 510-511
DOI: 10.1126/science.298.5593.510

You are currently viewing the summary.

View Full Text

Summary

An expert panel, meeting in an emergency session last week, urged the U.S. Food and Drug Administration to lift a hold it had placed on three gene therapy trials after a patient treated with gene therapy in France developed cancer. The panel made the recommendation after concluding that the cancer was almost certainly caused by the gene therapy.